2. Search Result
Search Result
Results for "

DOPAC

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-42849A
    Sultopride hydrochloride
    1 Publications Verification

    LIN-1418 hydrochloride

    		 Dopamine Receptor Neurological Disease
    Sultopride hydrochloride (LIN-1418 hydrochloride) is a selective antagonist of dopamine D2 receptor.
    Sultopride hydrochloride
  • HY-15793
    NBI-98782
    1 Publications Verification

    (+)-DTBZ; (+)-α-Dihydrotetrabenazine; (+)-α-DHTBZ

    		 Monoamine Transporter Neurological Disease
    NBI-98782 is a high affinity and selectivity vesicular monoamine transporter 2 (VMAT2) inhibitor with a Ki of 3 nM. NBI-98782 has antipsychotic activity .
    NBI-98782
  • HY-14201
    Lazabemide

    Ro 19-6327

    		 Monoamine Oxidase Neurological Disease
    Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide ?inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and?alzheimer′s disease .
    Lazabemide
  • HY-19061
    CGP 28014

    		COMT Neurological Disease
    CGP 28014 is a catechol-O-methyltransferase inhibitor. CGP 28014 can lower HVA levels and increase DOPAC levels in the striatum of rats, making it useful for research on Parkinson's disease .
    CGP 28014
  • HY-19845A
    Ordopidine hydrochloride

    ACR-325 hydrochloride

    		 Dopamine Receptor Neurological Disease
    Ordopidine hydrochloride is a modulator of dopamine receptor extracted from patent WO/2005/121087A1, compound example 2; exhibits an ED50 of 68 μmol/kg on increase of DOPAC in the rat striatum.
    Ordopidine hydrochloride
  • HY-135242
    LY87130 free base

    		Adrenergic Receptor Endocrinology
    LY87130 free base is an octopamine-N-methyltransferase inhibitor with epinephrine-inhibiting activity. LY87130 free base can significantly reduce the basal level of epinephrine in the hypothalamus after administration. LY87130 free base has no significant effect on the basal levels of norepinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) in the hypothalamus .
    LY87130 free base
  • HY-42849
    Sultopride

    LIN-1418

    		 Dopamine Receptor Neurological Disease
    Sultopride (LIN-1418) is a selective antagonist of dopamine D2 receptor.
    Sultopride
  • HY-14202
    Lazabemide hydrochloride

    Ro 19-6327 hydrochloride

    		 Monoamine Oxidase Neurological Disease
    Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC50=0.03 μM) but less active for MAO-A (IC50>100 μM). Lazabemide  inhibits monoamine uptake at high concentrations, the IC50 values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease .
    Lazabemide hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: